Control Bionics (Australia) Performance
| CBL Stock | 0.07 0 1.47% |
Control Bionics holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.82, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Control Bionics will likely underperform. Use Control Bionics information ratio, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to analyze future returns on Control Bionics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Control Bionics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain essential indicators, Control Bionics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Control Bionics Reports Strong Q1 FY26 with Expanding Market Reach - TipRanks | 10/30/2025 |
2 | Control Bionics Soars 65 percent on Game-Changing Apple Integration - Stocks Down Under | 11/10/2025 |
3 | Applied Materials Q4 profit top estimates, stock drops as revenue and earnings decline - Proactive financial news | 11/14/2025 |
4 | Control Bionics Ltd. Announces Successful Shareholder Meeting Outcomes - The Globe and Mail | 11/25/2025 |
5 | Control Bionics seeks ASX quotation for 8.4 million new shares - MSN | 01/05/2026 |
| Begin Period Cash Flow | 980.8 K | |
| Total Cashflows From Investing Activities | -744.8 K |
Control |
Control Bionics Relative Risk vs. Return Landscape
If you would invest 3.20 in Control Bionics on October 25, 2025 and sell it today you would earn a total of 3.60 from holding Control Bionics or generate 112.5% return on investment over 90 days. Control Bionics is generating 1.6337% of daily returns assuming 9.879% volatility of returns over the 90 days investment horizon. Simply put, 88% of all stocks have less volatile historical return distribution than Control Bionics, and 68% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Control Bionics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Control Bionics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Control Bionics, and traders can use it to determine the average amount a Control Bionics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Estimated Market Risk
| 9.88 actual daily | 88 88% of assets are less volatile |
Expected Return
| 1.63 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Control Bionics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Control Bionics by adding it to a well-diversified portfolio.
Control Bionics Fundamentals Growth
Control Stock prices reflect investors' perceptions of the future prospects and financial health of Control Bionics, and Control Bionics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Control Stock performance.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 27.85 M | ||||
| Shares Outstanding | 411.96 M | ||||
| Price To Book | 5.09 X | ||||
| Price To Sales | 4.63 X | ||||
| Revenue | 6.14 M | ||||
| Gross Profit | 4.11 M | ||||
| EBITDA | (5.14 M) | ||||
| Net Income | (6.11 M) | ||||
| Total Debt | 435.4 K | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (4.27 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Total Asset | 8.23 M | ||||
| Retained Earnings | (35.39 M) | ||||
About Control Bionics Performance
Assessing Control Bionics' fundamental ratios provides investors with valuable insights into Control Bionics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Control Bionics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Control Bionics is entity of Australia. It is traded as Stock on AU exchange.Things to note about Control Bionics performance evaluation
Checking the ongoing alerts about Control Bionics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Control Bionics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Control Bionics is way too risky over 90 days horizon | |
| Control Bionics has some characteristics of a very speculative penny stock | |
| Control Bionics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 6.14 M. Net Loss for the year was (6.11 M) with profit before overhead, payroll, taxes, and interest of 4.11 M. | |
| Control Bionics generates negative cash flow from operations | |
| About 53.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Control Bionics seeks ASX quotation for 8.4 million new shares - MSN |
- Analyzing Control Bionics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Control Bionics' stock is overvalued or undervalued compared to its peers.
- Examining Control Bionics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Control Bionics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Control Bionics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Control Bionics' stock. These opinions can provide insight into Control Bionics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Control Stock Analysis
When running Control Bionics' price analysis, check to measure Control Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Control Bionics is operating at the current time. Most of Control Bionics' value examination focuses on studying past and present price action to predict the probability of Control Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Control Bionics' price. Additionally, you may evaluate how the addition of Control Bionics to your portfolios can decrease your overall portfolio volatility.